COI
DNLI icon

Connable Office Inc’s Denali Therapeutics DNLI Stock Holding History

Connable Office Inc’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,699
Closed -$212K – 214
2021
Q2 		$212K Buy
+2,699
New +$167K 0.03% 203

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Connable Office Inc's DNLI Position: Q3 2021 in Review

Connable Office Inc sold out of Denali Therapeutics (DNLI) in Q3 2021, closing a stake of 2,699 shares — an estimated $212K sold.

Connable Office Inc first reported a position in DNLI in Q2 2021 and held it in 1 quarter. The position peaked at $212K in Q2 2021. 214 funds tracked by Wall St. Rank hold DNLI as of Q3 2021.

  • Connable Office Inc reported no remaining Denali Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Connable Office Inc sold 2,699 Denali Therapeutics shares in Q3 2021, an estimated $212K.
  • Connable Office Inc first reported a position in Denali Therapeutics in Q2 2021 and held it in 1 quarter.
  • Connable Office Inc's Denali Therapeutics position peaked at $212K in Q2 2021.
  • 214 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2021.

Based on Connable Office Inc's 13F filing for Q3 2021, filed 9 Nov 2021.